BG105003A - Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer - Google Patents

Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer

Info

Publication number
BG105003A
BG105003A BG105003A BG10500300A BG105003A BG 105003 A BG105003 A BG 105003A BG 105003 A BG105003 A BG 105003A BG 10500300 A BG10500300 A BG 10500300A BG 105003 A BG105003 A BG 105003A
Authority
BG
Bulgaria
Prior art keywords
protein
combinations
hmg coa
farnesyltransfer
coa reductase
Prior art date
Application number
BG105003A
Other languages
Bulgarian (bg)
English (en)
Inventor
Judith Leopold
Roger NEWTON
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of BG105003A publication Critical patent/BG105003A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG105003A 1998-05-12 2000-11-29 Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer BG105003A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8520298P 1998-05-12 1998-05-12
US9225398P 1998-07-10 1998-07-10
PCT/US1999/010188 WO1999058505A2 (fr) 1998-05-12 1999-05-10 Combinaisons d'inhibiteurs de proteine farnesyltransferase et de hmg coa reductase et leurs utilisations dans le traitement du cancer

Publications (1)

Publication Number Publication Date
BG105003A true BG105003A (en) 2001-07-31

Family

ID=26772425

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105003A BG105003A (en) 1998-05-12 2000-11-29 Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer

Country Status (26)

Country Link
US (1) US6492410B1 (fr)
EP (1) EP1077949A2 (fr)
JP (1) JP2002514628A (fr)
KR (1) KR20010043529A (fr)
CN (1) CN1171874C (fr)
AP (1) AP2000001984A0 (fr)
AU (1) AU758891B2 (fr)
BG (1) BG105003A (fr)
BR (1) BR9911785A (fr)
CA (1) CA2331295A1 (fr)
EA (1) EA003860B1 (fr)
EE (1) EE200000660A (fr)
GE (1) GEP20032996B (fr)
HK (1) HK1038355A1 (fr)
HR (1) HRP20000771A2 (fr)
HU (1) HUP0102322A3 (fr)
ID (1) ID27933A (fr)
IL (1) IL139502A0 (fr)
IS (1) IS5713A (fr)
NO (1) NO20005680L (fr)
NZ (1) NZ508357A (fr)
OA (1) OA11551A (fr)
PL (1) PL344662A1 (fr)
SK (1) SK16742000A3 (fr)
WO (1) WO1999058505A2 (fr)
YU (1) YU68900A (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536405A (ja) * 1999-02-11 2002-10-29 イーデンランド、インコーポレイテッド ウイルス感染症の治療方法
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
US20020132781A1 (en) * 2000-10-06 2002-09-19 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor
GB0220885D0 (en) * 2002-09-09 2002-10-16 Novartis Ag Organic compounds
WO2005042710A1 (fr) * 2003-10-28 2005-05-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation de statines pour detruire des cellules b transformees par virus d'epstein-barr (veb)
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
KR100930365B1 (ko) * 2006-11-09 2009-12-08 덕성여자대학교 산학협력단 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물
US20080119444A1 (en) * 2006-11-16 2008-05-22 Steven Lehrer Methods and compositions for the treatment of cancer
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK523288A (da) * 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
NL9002031A (nl) 1990-09-14 1992-04-01 Voskuilen Woudenberg Bv Inrichting voor het bewerken van een uitwendig buisoppervlak.
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
WO1997000894A1 (fr) * 1995-06-22 1997-01-09 Novo Nordisk A/S Composes presentant des proprietes de liberation de l'hormone de croissance
WO1997000895A1 (fr) 1995-06-22 1997-01-09 Biogen, Inc. Cristaux de fragments du ligand cd40 et leur utilisation
UA57081C2 (uk) * 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування

Also Published As

Publication number Publication date
WO1999058505A2 (fr) 1999-11-18
CA2331295A1 (fr) 1999-11-18
BR9911785A (pt) 2001-04-03
WO1999058505A3 (fr) 2000-01-06
NO20005680L (no) 2001-01-10
EP1077949A2 (fr) 2001-02-28
JP2002514628A (ja) 2002-05-21
KR20010043529A (ko) 2001-05-25
HRP20000771A2 (en) 2001-06-30
EE200000660A (et) 2002-04-15
CN1171874C (zh) 2004-10-20
IL139502A0 (en) 2001-11-25
EA003860B1 (ru) 2003-10-30
HK1038355A1 (en) 2002-03-15
HUP0102322A2 (hu) 2001-11-28
AP2000001984A0 (en) 2000-12-31
PL344662A1 (en) 2001-11-19
ID27933A (id) 2001-05-03
GEP20032996B (en) 2003-06-25
NZ508357A (en) 2002-09-27
HUP0102322A3 (en) 2001-12-28
IS5713A (is) 2000-11-10
AU3979299A (en) 1999-11-29
CN1306515A (zh) 2001-08-01
YU68900A (sh) 2002-12-10
EA200001164A1 (ru) 2001-06-25
NO20005680D0 (no) 2000-11-10
OA11551A (en) 2004-05-24
AU758891B2 (en) 2003-04-03
US6492410B1 (en) 2002-12-10
SK16742000A3 (sk) 2001-07-10

Similar Documents

Publication Publication Date Title
TR200103216T2 (tr) Pirimidinon bileşimleri
ZA955411B (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
PL346797A1 (en) Arylsulfonanilide ureas
CA2288948A1 (fr) Arginine deiminase modifiee
NO308250B1 (no) 6-Arylpyrido[2,3-d]pyrimidiner og -naftyridiner og farmasøytiske preparater omfattende disse
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
YU6602A (sh) Pirimidin-2,4,6-trion metaloproteinazni inhibitori
DE69432035D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
WO2003103581A3 (fr) Compositions et methodes de croissance et de protection du foie
BG105003A (en) Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer
BG103832A (en) Leptin as tumour cells proliferation inhibitor
WO1996034113A3 (fr) Procedes d'identification d'inhibiteurs de transferases de farnesyl
AU2001259353A1 (en) Novel mutated form of arginine deiminase
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
PT951471E (pt) Inibidores cicloalquilo de farnesiltransferase de proteinas
AP2002002417A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
AU2990300A (en) Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof
WO2001037853A3 (fr) Procedes et agents d'inhibition de la proliferation des cellules du muscle lisse
IT1255470B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi